UBS AM’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-7,255
| Closed | -$206K | – | 2703 |
|
|
2023
Q2 | $206K | Hold |
7,255
| – | – | ﹤0.01% | 2565 |
|
|
2023
Q1 | $206K | Sell |
7,255
-544
| -7% | -$15.4K | ﹤0.01% | 2565 |
|
|
2022
Q4 | $228K | Hold |
7,799
| – | – | ﹤0.01% | 2411 |
|
|
2022
Q3 | $206K | Sell |
7,799
-5,143
| -40% | -$136K | ﹤0.01% | 2604 |
|
|
2022
Q2 | $575K | Sell |
12,942
-484
| -4% | -$21.5K | ﹤0.01% | 2254 |
|
|
2022
Q1 | $664K | Buy |
13,426
+1,443
| +12% | +$71.4K | ﹤0.01% | 2350 |
|
|
2021
Q4 | $610K | Buy |
11,983
+211
| +2% | +$10.7K | ﹤0.01% | 2472 |
|
|
2021
Q3 | $657K | Buy |
11,772
+5,243
| +80% | +$292K | ﹤0.01% | 2373 |
|
|
2021
Q2 | $279K | Hold |
6,529
| – | – | ﹤0.01% | 2657 |
|
|
2021
Q1 | $273K | Hold |
6,529
| – | – | ﹤0.01% | 2504 |
|
|
2020
Q4 | $304K | Hold |
6,529
| – | – | ﹤0.01% | 2407 |
|
|
2020
Q3 | $277K | Hold |
6,529
| – | – | ﹤0.01% | 2329 |
|
|
2020
Q2 | $313K | Buy |
6,529
+128
| +2% | +$6.14K | ﹤0.01% | 2267 |
|
|
2020
Q1 | $294K | Sell |
6,401
-3,714
| -37% | -$171K | ﹤0.01% | 2159 |
|
|
2019
Q4 | $608K | Buy |
10,115
+3,414
| +51% | +$205K | ﹤0.01% | 2158 |
|
|
2019
Q3 | $379K | Hold |
6,701
| – | – | ﹤0.01% | 2380 |
|
|
2019
Q2 | $373K | Hold |
6,701
| – | – | ﹤0.01% | 2334 |
|
|
2019
Q1 | $338K | Buy |
6,701
+1,401
| +26% | +$70.7K | ﹤0.01% | 2265 |
|
|
2018
Q4 | $214K | Hold |
5,300
| – | – | ﹤0.01% | 2362 |
|
|
2018
Q3 | $367K | Hold |
5,300
| – | – | ﹤0.01% | 2209 |
|
|
2018
Q2 | $401K | Buy |
+5,300
| New | +$401K | ﹤0.01% | 2190 |
|
|
2016
Q4 | – | Sell |
-3,500
| Closed | -$245K | – | 2689 |
|
|
2016
Q3 | $245K | Buy |
+3,500
| New | +$245K | ﹤0.01% | 2366 |
|
|
2016
Q1 | – | Sell |
-3,900
| Closed | -$346K | – | 2676 |
|
|
2015
Q4 | $346K | Hold |
3,900
| – | – | ﹤0.01% | 2270 |
|
|
2015
Q3 | $289K | Buy |
3,900
+400
| +11% | +$29.6K | ﹤0.01% | 2307 |
|
|
2015
Q2 | $283K | Buy |
+3,500
| New | +$283K | ﹤0.01% | 2401 |
|